Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IB Trial of Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors

Trial Profile

A Phase IB Trial of Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2019

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Vorolanib (Primary)
  • Indications Gastric cancer; Liver cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jan 2019 Trial design presented at the 2019 Gastrointestinal Cancers Symposium
    • 18 Sep 2018 Planned End Date changed from 28 Feb 2022 to 31 Mar 2022.
    • 18 Sep 2018 Planned primary completion date changed from 30 Sep 2019 to 31 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top